Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease

Expert Review of Clinical Immunology

Volumn 6, Issue 4, 2010, Pages 551-558

  Caccaro, Roberta ^a   Dinc, Renata ^a   Sturniolo, Giacomo Carlo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

calprotectin; disease markers; fecal markers; IBD; lactoferrin

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; BUDESONIDE; CALGRANULIN; INFLIXIMAB; LACTOFERRIN; MESALAZINE; METHOTREXATE; PREDNISONE;

CHRONIC INFLAMMATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; ENDOSCOPY; ENTERITIS; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; LABORATORY TEST; POSTOPERATIVE CARE; REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FECES; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; LACTOFERRIN; LEUKOCYTE L1 ANTIGEN COMPLEX; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 77954410995     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.26     Document Type: Review

References (61)

1. Stange EF, Travis SPL, Vermeire S et al. European evidence-based consensus on the diagnosis and management of Crohn's disease: defnitions and diagnosis. Gut 55, i1-i15 (2006). (Pubitemid 43268290)
2. Stange EF, Travis SPL, Vermeire S et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: defnitions and diagnosis. Journal of Crohn's and Colitis 2, 1-23 (2008). (Pubitemid 351179487)
3. Tibble JA, Bjarnason I. Non-invasive investigation of infammatory bowel disease. World J. Gastroenterol. 7(4), 460-465 (2001). (Pubitemid 32782620)
4. Saverymuttu SH, Camilleri M, Rees H et al. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in infammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology 90(5 Pt 1), 1121-1128 (1986). (Pubitemid 16145475)
5. Leddin DJ, Paterson WG, Da Costa LR et al. Indium-111-labeled autologous leukocyte imaging and faecal excretion. Comparison with conventional methods of assessment of infammatory bowel disease. Dig. Dis. Sci. 32(4), 377-387 (1987).
6. Roseth AG, Schmidt PN, Fagerhal MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with infammatory bowel disease. Scand. J. Gastroenterol. 34, 50-54 (1999).
7. Guerrant RL, Araujo V, Soares E et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J. Clin. Microbiol. 30, 1238-1242 (1992).
8. Oseas R, Yang HH, Baehner RL et al. Lactoferrin: a promoter of polymorphonuclear leucocyte adhesiveness. Blood 57(5), 939-945 (1981). (Pubitemid 11096488)
9. Palmon R, Brown SJ, Abreu MT. What is the role and signifcance of serum and stool biomarkers in the diagnosis of IBD? Infamm. Bowel Dis. 14, S187-S189 (2008).
10. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55, 426-431 (2006).
11. Olafsdottir E, Aksnes L, Fluge G, Bertstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with infammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Pediatr. 91(1), 45-50 (2002). (Pubitemid 34151218)
12. Carroccio A, Iacono G, Cottone M et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhoea from irritable bowel syndrome: a prospective study in adults and children. Clin. Chem. 49(6), 861-867 (2003). (Pubitemid 36623463)
13. Quail MA, Russel RK, Van Limbergen JE et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood infammatory bowel disease. Infamm. Bowel Dis. 15, 756-759 (2009).
14. Joishy M, Davies I, Ahmed M et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric infammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 48, 48-54 (2009).
15. Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F. Accuracy of four fecal assays in the diagnosis of colitis. Dis. Colon Rectum. 50, 1697-1706 (2007). (Pubitemid 47583348)
16. Limburg PJ, Ahlquist DA, Sandborn WJ et al. Fecal calprotectin levels predict colorectal infammation among patients with chronic diarrhea referred for colonoscopy. Am. J. Gastroenterol. 95, 2831-2837 (2000).
17. Schroder O, Naumann M, Shastri Y, Povse N, Stein J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal infammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment. Pharmacol. Ther. 26, 1035-1042 (2007). (Pubitemid 47416301)
18. Hirata I, Hoshimoto M, Saito O et al. Usefulness of faecal lactoferrin and haemoglobin in diagnosis of colorectal diseases. World J. Gastroenterol. 13(10), 1569-1574 (2007). (Pubitemid 46672666)
19. Meucci G, D'Incà R, Maieron R et al Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: a multicenter prospective study. Dig. Liver Dis. 42, 191-195 (2010).
20. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of infammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 123, 450-460 (2002). (Pubitemid 34827189)
21. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmidt B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Infamm. Bowel Dis. 14, 32-39 (2008). (Pubitemid 351196866)
22. Wassell J, Dolwani S, Metzner M, Losty H, Hawthorne A. Faecal calprotectin: a new marker for Crohn's disease? Ann. Clin. Biochem. 41, 230-232 (2004). (Pubitemid 38623150)
23. Tibble J, Teahon K, Thjodleifsson B et al A simple method for assessing intestinal infammation in Crohn's disease. Gut 47, 506-513 (2000).
24. Von Roon AC, Karamountzos L, Purkayastha S et al. Diagnostic precision of faecal calprotectin for infammatory bowel disease and colorectal malignancy. Am. J. Gastroenterol. 102, 803-813 (2007). (Pubitemid 46496634)
25. D'Incà R, Dal Pont E, Di Leo V et al Calprotectin and lactoferrin in the assessment of intestinal infammation and organic disease. Int. J. Colorectal Dis. 22, 429-437 (2007). (Pubitemid 46336248)
26. Sandborn WJ, Feagan BG, Hanauer SB et al. A review of activity indeced and effcacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122, 512-530 (2002).
27. Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in infammatory bowel disease. Infamm. Bowel Dis. 15, 1746-1754 (2009).
28. Fagerberg UL, Loof L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic infammation in children with infammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 45, 414-420 (2007). (Pubitemid 350307158)
29. Berni Canani R, Terrin G, Rapacciuolo L et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal infammation in children with infammatory bowel disease. Dig. Liver Dis. 40, 547-553 (2008).
30. Langhorst J, Elsenbruch S, Mueller T et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Infamm. Bowel Dis. 11(12), 1085-1091 (2005). (Pubitemid 41682565)
31. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal infammation in infammatory bowel diseases: performance of faecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indexes. Am. J. Gastroenterol. 103, 162-169 (2008).
32. Sipponen T, Karkkainen P, Savilahti E et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological fndings. Aliment. Pharmacol. Ther. 28, 1221-1229 (2008). (Pubitemid 351196867)
33. Sipponen T, Savilahti E, Kohlo KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic fndings. Infamm. Bowel Dis. 14, 40-46 (2008). (Pubitemid 351196867)
34. Vieira A, Fang CB, Rolim EG et al. Infammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res. Notes 2, 221 (2009).
35. Schoepfer AM, Beglinger C, Straumann A et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am. J. Gastroenterol. 105(1), 162-169 (2010).
36. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Infamm. Bowel Dis. 15, 1851-1858 (2009).
37. Amati L, Passeri ME, Selicato F et al. New insights into the biological and clinical signifcance of fecal calprotectin in infammatory bowel disease. Immunopharmacol. Immunotoxicol. 28(4), 665-681 (2006). (Pubitemid 46026369)
38. Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric infammatory bowel disease. Infamm. Bowel Dis. 14, 669-673 (2008). (Pubitemid 351742984)
39. Tibble JA, Sighthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal infammation are predictive of relapse in patients with infammatory bowel disease. Gastroenterology 119, 15-22 (2000). (Pubitemid 30452574)
40. Costa F, Mumolo MG, Ceccarelli L et al Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 54, 364-368 (2005). (Pubitemid 40299092)
41. Hanaway P, Roseth A. Infammatory biomarkers predict relapse in IBD. Gut 54, 1346-1347 (2005). (Pubitemid 41192505)
42. D'Incà R, Dal Pont E, Di Leo V et al. Can calprotectin predict relapse risk in infammatory bowel disease? Am. J. Gastroenterol. 103, 2007-2014 (2008).
43. Gisbert JP, Bermejo F, Pérez-Calle JL et al Fecal calprotectin and lactoferrin for the prediction of infammatory bowel disease relapse. Infamm. Bowel Dis. 15(8), 1190-1198 (2009).
44. Ho GT, Lee HM, Brydon G et al. Fecal calprotectin predicts the clinical course of acute severe colitis. Am. J. Gastroenterol 104, 673-678 (2009).
45. Damms A, Bischoff SC. Validation and clinical signifcance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int. J. Colorectal Dis. 23, 985-992 (2008).
46. Elkjaer M, Burisch J, Voxen Hansen V et al. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment. Pharmacol. Ther. 31(2), 323-330 (2010).
47. Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infiximab therapy. Dig. Dis. Sci. 49(6), 1036-1039 (2004). (Pubitemid 39012291)
48. Sipponen T, Savilahti E, Karkkainen P et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-a therapy for Crohn's disease. Infamm. Bowel Dis. 14(10), 1392-1398 (2008). (Pubitemid 351196867)
49. Wagner M, Peterson CGB, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of infammation used as surrogate markers for treatment outcome in relapsing infammatory bowel disease. World J. Gastroenterol. 14(36), 5584-5589 (2008).
50. Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with infammatory bowel disease. Scand. J. Gastroenterol. 41, 720-725 (2006). (Pubitemid 43995015)
51. Sipponen T, Bjokesten CLA, Farkkila M et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand. J. Gastroenterol. 45(3), 325-331 (2009).
52. Orlando A, Modesto I, Castiglione F et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound. Eur. Rev. Med. Pharmacol. Sci. 10(1), 17-22 (2006). (Pubitemid 43299605)
53. Lamb CA, Mohiuddin MK, Gicquel J et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br. J. Surg. 96, 663-674 (2009).
54. Scarpa M, D'Incà R, Basso D et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease. Dis. Colon Rectum. 50, 861-867 (2007). (Pubitemid 46870452)
55. Ruffolo C, Scarpa M, Faggian D et al. Subclinical intestinal infammation in patients with Crohn's disease following bowel resection: a smoldering fre. J. Gastrointest. Surg. 14, 24-31 (2010).
56. Navaneethan U, Shen B. Laboratory tests for patients with ileal-pouch-anal anastomosis: clinical utility in predicting, diagnosing, and monitoring pouch disorders. Am. J. Gastroenterol. 104(10), 2606-2615 (2009).
57. Thomas P, Rihani H, Roseth A et al Assessment of ileal pouch infammation by single-stool calprotectin assay. Dis. Colon Rectum 43, 214-220 (2000). (Pubitemid 30115103)
58. Johnson MW, Maestranzi S, Duffy AM et al. faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur. J. Gastroenterol. Hepatol. 20, 174-179 (2008). (Pubitemid 351317353)
59. Parsi MA, Shen B, Achar JP et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology 126, 1280-1286 (2004). (Pubitemid 38552792)
60. Lim M, Gonsalves S, Thekkinkattil D et al. The assessment of a rapid non invasive immunochromatographic assay test for fecal lactoferrin in patients with suspected infammation of the ileal pouch. Dis. Colon Rectum 51(1), 96-99 (2008).
61. Pakarinen MP, Koivusalo A, Natunen J et al. Fecal calprotectin mirrors infammation of the distal ileum and bowel function after restorative proctocolectomy for pediatric-onset ulcerative colitis. Infamm. Bowel Dis. 13(3), 482-486 (2009).